Telix Pharmaceuticals Limited (TLX) News
Track canonical SquawkNews coverage tagged to TLX, Telix Pharmaceuticals Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
TLX - Telix H1 2026 Results: Investor Webcast Notification
TLX - Telix H1 2026 Results: Investor Webcast Notification
EQUITY | Jul 30, 2026, 10:37 PM UTC
H
Reported Earlier, Telix FY2026 Revenue Guidance $950M-$970M Plus $40M Regeneron Payment, Total Expected Above $1B
Reported Earlier, Telix FY2026 Revenue Guidance $950M-$970M Plus $40M Regeneron Payment, Total Expected Above $1B
EARNINGS | Jul 21, 2026, 06:43 AM UTC
H
Telix Pharmaceuticals price target lowered to $22 from $22.50 at Citi
Citi lowered the firm's price target on Telix Pharmaceuticals to $22 from $22.50 and keeps a Buy rating on the shares. Q2 Visible Alpha consensus of $184M in Illuccix/Gozellix sales "looks reasonable," says the analyst,
EQUITY | Jul 07, 2026, 04:51 PM UTC
L
Reported Earlier, Telix Achieves FDA Alignment On Clinical Protocol And Statistical Framework Across Three Standard Of Care Combination Coho
Reported Earlier, Telix Achieves FDA Alignment On Clinical Protocol And Statistical Framework Across Three Standard Of Care Combination Cohorts
REGULATION | Jul 02, 2026, 06:53 AM UTC
L
TLX Updates Neuro-Oncology
Telix hosts educational webinar on neuro-oncology portfolio update and future therapeutic directions
EQUITY | Jun 22, 2026, 09:40 PM UTC